Tamper Evidence in Pharma Packaging

The anti-counterfeit packaging market is forecasted to reach US$206.57 billion by 2021, just shy of doubling its 2016 figure of $107.26 bn. This growth is supported by the expanding pharma and food and beverage industries, with Asia Pacific set to take the largest market share. China is earmarked to lead the way in 2021 with its drive in manufacturing activities fuelling that lead.

The anti-tampering market is littered with challenges to address: meeting EU FMD requirements, satisfying country specific requirements, preserving patient usability and not to mention outwitting resourceful counterfeiters. Ahead of the Packaging and Labelling Summit in June Pharma IQ explores the world of tamper evidence in pharma packaging

Insight from

	Dieter Mößner Convenor of ISO TC Edelmann GmbH 122 WG 15 “Tamper Verification Features on medicinal product packaging
	Horst Kastrup Senior Regulatory Advisor MEDA Pharma

Topics Discussed

• The road to meeting the 2019 FMD deadline

• Finding the most suitable antitamper evidence feature

• Efficient tamper evidence packaging that is also patient friendly

• Future trends

• About Packaging and Labelling 2017

[inlinead]